Citation Impact
Citing Papers
Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei
2004 Standout
Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation
2014
Hallmarks of Cancer: The Next Generation
2011 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Radiotherapy for renal-cell carcinoma
2014
Clinical trials in primary hepatocellular carcinoma: current status and future directions
1988
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers
2005
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Marine-derived anticancer agents in clinical trials
2003
A Prospective Randomized Trial of Regional Versus Systemic Continuous 5-Fluorodeoxyuridine Chemotherapy in the Treatment of Colorectal Liver Metastases
1987
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
2013
Marine natural products
1990 Standout
Relationships between body composition parameters and fluorouracil pharmacokinetics
2002
Phase II trial of dolastatin-10 in patients with advanced breast cancer
2005
Drug development from marine natural products
2008 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
Anticancer therapy with novel tubulin-interacting drugs
2001
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Fluorouracil: biochemistry and pharmacology.
1988
The oligometastatic state—separating truth from wishful thinking
2014
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
The Structures of Antibiotics Bound to the E Site Region of the 50 S Ribosomal Subunit of Haloarcula marismortui: 13-Deoxytedanolide and Girodazole
2007 StandoutNobel
Management of Hepatocellular Carcinoma *
2005 Standout
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer
2008
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
2001 Standout
Peritonectomy Procedures
1995 Standout
Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas
1996
Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer
2009
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases
1988
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
2010 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Intraoperative detection and removal of microscopic residual sarcoma using wide‐field imaging
2012 StandoutNobel
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Alternative Activation of Macrophages: Mechanism and Functions
2010 Standout
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
2010
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Microtubules as a target for anticancer drugs
2004 Standout
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms
2013 Standout
Protective and pathogenic functions of macrophage subsets
2011 Standout
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Local treatments for metastases of renal cell carcinoma: a systematic review
2014
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
1999 Standout
Knocking down barriers: advances in siRNA delivery
2009 Standout
Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis , , ,
2014
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival
2009
Clinical Pharmacology of 5-Fluorouracil
1989 Standout
13-Deoxytedanolide, a marine sponge-derived antitumor macrolide, binds to the 60S large ribosomal subunit
2004
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
2014
Update on tubulin-binding agents
2005
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
2003
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Marine natural product drug discovery: Leads for treatment of inflammation, cancer, infections, and neurological disorders
2010
Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors
2005
Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models
2007
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
2009 Standout
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Structures of Triacetyloleandomycin and Mycalamide A Bind to the Large Ribosomal Subunit of Haloarcula marismortui
2009 StandoutNobel
The “Utility” of Highly Toxic Marine-Sourced Compounds
2019
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Alternative activation of tumor-associated macrophages by IL-4
2010
Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
2005
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity
2016 Standout
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
2011
Cancer, Clinical Pharmacology, and Aging
1987
Isolation and Structure Determination of Malevamide E, a Dolastatin 14 Analogue, from the Marine Cyanobacterium Symploca laete-viridis
2008
A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin.
1979
Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma.
1984
Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen
2006
Pharmacological Developments Obtained from Marine Natural Products and Current Pipeline Perspective
2011
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison
2007
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
2010 Standout
Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.
1981
Targeted drug delivery
1986
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
2017
The Anthracycline Antineoplastic Drugs
1981 Standout
Breast Cancer in Men
2002 Standout
Works of Michael Glodé being referenced
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control
2011
Phase II Trial of Recombinant Human Interleukin-4 in Patients With Advanced Renal Cell Carcinoma: A Southwest Oncology Group Study
2002
Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
2000
Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC)
2007
Evaluation of CEA and GCDFP-15 plasma level during hormonally induced cancer stimulation.
1984
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.
1978
Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer
2008